MNTA Stock UPDATES Momenta Pharmaceuticals (MNTA) 11.13 10/21/2014
Post# of 273217
Biotech Equities Technical Briefing - Arena Pharma, NPS Pharma, XOMA, Momenta Pharma, and Catalyst Pharma Partners
PR Newswire - Fri Oct 17, 8:30AM CDT
Investor-Edge has initiated coverage on the following equities: Arena Pharmaceuticals Inc. (NASDAQ: ARNA), NPS Pharmaceuticals Inc. (NASDAQ: NPSP), XOMA Corporation (NASDAQ: XOMA), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), and Catalyst Pharmaceutical Partners Inc. (NASDAQ: CPRX). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Thursday, October 16, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 16,117.24, down 0.15% and the NASDAQ Composite closed at 4,217.39, up 0.05%. The S&P 500 finished the session 0.01% higher at 1,862.76. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 696.64, down 0.50%, whereas the index has advanced 8.46% on YTD basis. Register for your complimentary reports on these five stocks at:
CPRX: 2.55 (+0.10), NPSP: 28.69 (+0.24), MNTA: 11.13 (-0.08), ARNA: 4.16 (-0.01), XOMA: 4.27 (+0.02)
Why Teva Pharmaceutical (TEVA) Stock Is Falling Today
at The Street - Wed Oct 15, 1:53PM CDT
Teva Pharmaceutical Industries (TEVA) stock is lower as the company faces uncertainty as U.S Supreme Court hears a patent case about its best selling drug Copaxone.
MYL: 52.04 (+1.73), TEVA: 53.26 (+1.57), MNTA: 11.13 (-0.08), NVS: 88.61 (+0.71)
Supreme Court weighs generic drug dispute
By SAM HANANEL - AP - Wed Oct 15, 12:51PM CDT
WASHINGTON (AP) — The Supreme Court seems divided as it considers a high-stakes patent dispute between rival pharmaceutical companies over the world's best-selling multiple sclerosis treatment.
MYL: 52.04 (+1.73), TEVA: 53.26 (+1.57), MNTA: 11.13 (-0.08)
Momenta Pharmaceuticals (MNTA) in Focus: Stock Up 5.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 15, 8:25AM CDT
Momenta Pharmaceuticals (MNTA) was a big mover last session, with shares rising nearly 6% on the day.
MYGN: 36.68 (+1.68), HALO: 9.12 (-0.03), LGND: 50.65 (+0.41), MNTA: 11.13 (-0.08)
Weakness Seen in Momenta Pharmaceuticals (MNTA): Stock Tumbles 13.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 13, 7:30AM CDT
Momenta Pharmaceuticals saw a big move last session, as the company’s shares fell by almost 14% on the day.
MACK: 8.68 (unch), EBS: 21.21 (-0.40), LGND: 50.65 (+0.41), MNTA: 11.13 (-0.08)
Momenta Reveals Necuparanib Data for Pancreatic Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Oct 10, 3:45PM CDT
Momenta Pharmaceuticals, Inc. (MNTA) announced top-line results from the part A portion of a phase I/II study on necuparanib for advanced metastatic pancreatic cancer.
MDVN: 96.97 (+1.99), TEVA: 53.26 (+1.57), MNTA: 11.13 (-0.08), NVS: 88.61 (+0.71)
Momenta Pharmaceuticals Announces Top-Line Part A Results From Phase 1/2 Trial of Necuparanib in Patients With Pancreatic Cancer
GlobeNewswire - Thu Oct 09, 3:15PM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, announced top-line results from the dose-escalation component (Part A) of the Phase 1/2 trial evaluating necuparanib in combination with Abraxane (ABX; nab-paclitaxel) and gemcitabine (GEM) in patients with advanced metastatic pancreatic cancer (ClinicalTrials.gov Identifier NCT01621243). A dose was established to take forward into Part B (Phase 2) of the trial, which is a randomized, controlled, proof-of-concept study to evaluate the antitumor activity of necuparanib in combination with ABX and GEM, compared with ABX and GEM alone.
MNTA: 11.13 (-0.08)
PGJ, ENY, APH, MNTA, PTNR, IM Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Thu Oct 09, 7:22AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of PowerShares Golden Dragon Halter USX China Portfolio (NYSE GJ), GUGGENHEIM CANADIAN ENERGY I (NYSE:ENY), AMPHENOL CORPORATION (NYSE:APH), Momenta Pharmaceuticals Inc (NASDAQ:MNTA), Partner Communications Company Ltd (NASDAQ TNR), Ingram Micro Inc (NYSE:IM) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
APH: 49.67 (+1.41), IM: 24.45 (+0.74), ENY: 14.17 (+0.37), PTNR: 7.07 (+0.11), PGJ: 30.11 (+0.55), MNTA: 11.13 (-0.08)
Global Pancreatic Cancer Market 2014-2018: Key Vendors are Celgene, Eli Lilly, F. Hoffmann-La Roche, Novartis and Pfizer
M2 - Thu Oct 09, 4:18AM CDT
Research and Markets (http://www.researchandmarkets.com/research/cmjxws/global_pancreatic) has announced the addition of the "Global Pancreatic Cancer Market 2014-2018" report to their offering. Pancreatic cancer is a malignant cells form in the tissues of pancreas. Based on the initiation, pancreatic cancer can be classified into exocrine pancreatic cancer and endocrine pancreatic cancer. When pancreatic cancer cells spread from the pancreas to other parts of the body, it is known as metastatic pancreatic order. The incidence and mortality rate of pancreatic cancer is higher in men than in women. SEER estimates that there were 46,420 new pancreatic cancer cases recorded in the US in 2014. It also estimated that 39,590 deaths occurred in the US in 2014 as a result of pancreatic cancer, accounting for 6.8 percent of the total cancer deaths in the US. The analysts forecast the Global Pancreatic Cancer market to grow at a CAGR of 10.70 percent over the period 2013-2018. This report covers the present scenario and the growth prospects of the Global Pancreatic Cancer market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various drugs administered to treat different types of pancreatic cancer. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by Type of Therapy 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis 18. Other Reports in this Series Companies Mentioned: - AB Science - AbGenomics International - Aduro Biotech - Aphios - Celgene - Celsion - Eli Lilly - F. Hoffmann-La Roche - Gilead Sciences - Halozyme Therapeutics - Merrimack Pharmaceuticals - Momenta Pharmaceuticals - Novartis - OncoMed Pharmaceuticals - OncozymePharma - Ostuka Holdings - Pfizer - Rexahn Pharmaceuticas - Zeria Pharmaceutica For more information visit http://www.researchandmarkets.com/research/cm...pancreatic
MACK: 8.68 (unch), OMED: 19.81 (+0.60), GILD: 106.67 (+4.46), LLY: 64.68 (+1.58), MNTA: 11.13 (-0.08), NVS: 88.61 (+0.71), CELGZ: 3.57 (-0.14)
Metastatic Pancreatic Cancer - Pipeline Review, H2 2014
M2 - Wed Oct 08, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hnpdbv/metastatic) has announced the addition of the "Metastatic Pancreatic Cancer - Pipeline Review, H2 2014" report to their offering. This, Metastatic Pancreatic Cancer - Pipeline Review, H2 2014', provides an overview of the Metastatic Pancreatic Cancer's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned: - F. Hoffmann-La Roche - AstraZeneca - Eli Lilly and Company - GlaxoSmithKline - Gilead Sciences - Merck & Co - FibroGen - Novartis AG - Pfizer Inc. - Silence Therapeutics plc - Celgene Corporation - Bayer AG - Incyte Corporation - Halozyme Therapeutics, Inc. - Momenta Pharmaceuticals, Inc. - Immunomedics, Inc. - Oncolytics Biotech Inc. - Synta Pharmaceuticals Corp. - NanoCarrier Co., Ltd. - Rexahn Pharmaceuticals, Inc. - Colby Pharmaceutical Company - INSYS Therapeutics, Inc. - OncoMed Pharmaceuticals, Inc. - Merrimack Pharmaceuticals, Inc. - Cornerstone Pharmaceuticals, Inc. - Pharma Mar, S.A. - Oncovir, Inc. - Cantex Pharmaceuticals, Inc. - Regulon Inc. - Fountain Biopharma Inc. - Oncozyme Pharma Inc. - AbbVie Inc. - Precision Biologics, Inc. For more information visit http://www.researchandmarkets.com/research/hnpdbv/metastatic
RNN: 0.71 (unch), IMMU: 3.65 (unch), ONCY: 0.47 (-0.06), OMED: 19.81 (+0.60), PFE: 28.28 (+0.35), INCY: 52.44 (+1.65), LLY: 64.68 (+1.58), GSK: 43.63 (+0.02), MNTA: 11.13 (-0.08), MACK: 8.68 (unch), SNTA: 3.06 (-0.07), INSY: 38.81 (-0.22), HALO: 9.12 (-0.03), GILD: 106.67 (+4.46), MRK: 55.13 (+1.08), ABBV: 56.29 (+1.88), NVS: 88.61 (+0.71), CELGZ: 3.57 (-0.14)
Momenta Pharmaceuticals to Host 2014 R&D Day
GlobeNewswire - Thu Oct 02, 7:00AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will host a live webcast of its 2014 R&D Day for investors and analysts on Friday, October 10, 2014 in New York City. Momenta plans to discuss its necuparanib (formerly M402), biosimilars and novel drug development programs, and provide an update on M356, the Company's generic version of Copaxone developed in collaboration with Sandoz. The webcasted presentations and Q&A will begin at 8:30 a.m. ET and are expected to conclude at 12:00 p.m. ET.
MNTA: 11.13 (-0.08)
Momenta Pharmaceuticals to Webcast Presentation at BioCentury's NewsMakers in the Biotech Industry Conference
GlobeNewswire - Wed Sep 17, 8:27AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will present at the BioCentury NewsMakers in the Biotech Industry Conference on Friday, September 26 at 3:00 p.m. ET. Momenta will provide a company overview and program update, including comments on necuparanib (formerly M402), biosimilars and M356, the Company's generic version of Copaxone developed in collaboration with Sandoz.
MNTA: 11.13 (-0.08)
Momenta Gains on Purchase of Autoimmune Antibodies - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 11, 4:45PM CDT
Momenta Pharmaceuticals, Inc. (MNTA) will use the antibodies acquired from AnaptysBio for developing a novel recombinant antibody targeting specific autoimmune disorders.
OPXA: 0.98 (+0.10), GILD: 106.67 (+4.46), BAX: 68.65 (+0.71), MNTA: 11.13 (-0.08)
Momenta Pharmaceuticals reports exercise of option to purchase novel antibody programme from AnaptysBio
M2 - Tue Sep 09, 6:22AM CDT
Biotechnology company Momenta Pharmaceuticals (NasdaqGS:MNTA) revealed on Monday the exercise of its option to acquire a novel antibody programme from AnaptysBio for an option exercise fee.
MNTA: 11.13 (-0.08)
Momenta Pharmaceuticals Exercises Option to Acquire Novel Antibodies From AnaptysBio
GlobeNewswire - Mon Sep 08, 7:30AM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it has exercised its option to acquire novel antibodies generated by AnaptysBio, Inc., a privately-held therapeutic antibody company, as part of the previously announced agreement between the two companies.
MNTA: 11.13 (-0.08)
Momenta Pharmaceuticals Exercises Option to Acquire Novel Antibody Program from AnaptysBio
PR Newswire - Mon Sep 08, 7:30AM CDT
AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced that Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, has exercised its option to acquire a novel antibody program from AnaptysBio. Upon payment of an option exercise fee to AnaptysBio, Momenta has received worldwide rights to therapeutic antibodies against a target selected based upon the anti-inflammatory effects of IVIg. The aforementioned option right was granted by AnaptysBio to Momenta under an agreement signed between the companies in December 2013.
MNTA: 11.13 (-0.08)
Momenta-Sandoz's Generic Copaxone Accepted for Review by FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 29, 2:20PM CDT
Momenta Pharmaceuticals (MNTA) announced that the FDA has accepted Sandoz's abbreviated new drug application for generic Copaxone for review.
GILD: 106.67 (+4.46), TEVA: 53.26 (+1.57), MNTA: 11.13 (-0.08), NVS: 88.61 (+0.71)
Momenta Pharmaceuticals Announces Abbreviated New Drug Application for Three-Times-a-Week Generic Copaxone Accepted for Review by FDA
GlobeNewswire - Thu Aug 28, 10:43AM CDT
Momenta Pharmaceuticals (Nasdaq:MNTA) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Abbreviated New Drug Application (ANDA) for a three-times-a-week generic COPAXONE(R) (glatiramer acetate injection, 40 mg/mL), submitted by Sandoz Inc., Momenta's development and commercialization partner for this product candidate.
MNTA: 11.13 (-0.08)
Technical Roundup on Biotech Stocks -- Medivation, Ironwood Pharma, Momenta Pharma, Galectin Therapeutics, and PDL BioPharma
PR Newswire - Tue Aug 12, 7:50AM CDT
The trading session on Monday, August 11, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,569.98, up 0.10% and the NASDAQ Composite closed at 4,401.33, up 0.70%. The S&P 500 finished the day 0.28% higher at 1,936.92. During the trading session seven out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day at 700.04, up 0.01%, and the index has advanced 4.74% in the previous three months. Investor-Edge has initiated coverage on the following equities: Medivation Inc. (NASDAQ: MDVN), Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), Galectin Therapeutics Inc. (NASDAQ: GALT) and PDL BioPharma Inc. (NASDAQ: PDLI). Free research on these five companies can be accessed at:
MDVN: 96.97 (+1.99), IRWD: 13.15 (+0.10), GALT: 5.09 (+0.03), MNTA: 11.13 (-0.08), PDLI: 8.17 (+0.13)
Momenta Posts Narrower Q2 Loss, Revenues Up Y/Y, Shares Gain - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 10:50AM CDT
Momenta Pharmaceuticals Inc. (MNTA) reported second-quarter 2014 net loss per share of 51 cents, wider than the Zacks Consensus Estimate of a loss of 49 cents but narrower than the year-ago loss of 57 cents.
BAX: 68.65 (+0.71), MNTA: 11.13 (-0.08), NVS: 88.61 (+0.71)